JP2000516262A - エレトリプタンヘミスルフェートおよびカフェインを含有する医薬組成物 - Google Patents
エレトリプタンヘミスルフェートおよびカフェインを含有する医薬組成物Info
- Publication number
- JP2000516262A JP2000516262A JP11506381A JP50638199A JP2000516262A JP 2000516262 A JP2000516262 A JP 2000516262A JP 11506381 A JP11506381 A JP 11506381A JP 50638199 A JP50638199 A JP 50638199A JP 2000516262 A JP2000516262 A JP 2000516262A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- present
- ethanol
- caffeine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 title claims abstract description 50
- IYVZCNNIKYUHHM-WXMGBDCWSA-N OS(O)(=O)=O.CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1.CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 Chemical compound OS(O)(=O)=O.CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1.CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 IYVZCNNIKYUHHM-WXMGBDCWSA-N 0.000 title claims abstract description 39
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 229960001948 caffeine Drugs 0.000 title claims abstract description 25
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 239000000203 mixture Substances 0.000 claims description 99
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 82
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 75
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 208000019695 Migraine disease Diseases 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 235000006708 antioxidants Nutrition 0.000 claims description 12
- 206010027599 migraine Diseases 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 229960005070 ascorbic acid Drugs 0.000 claims description 9
- 235000010323 ascorbic acid Nutrition 0.000 claims description 9
- 239000011668 ascorbic acid Substances 0.000 claims description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000006561 Cluster Headache Diseases 0.000 claims description 4
- 208000030814 Eating disease Diseases 0.000 claims description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 206010047700 Vomiting Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 4
- 235000014632 disordered eating Nutrition 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 230000001314 paroxysmal effect Effects 0.000 claims description 4
- 201000009032 substance abuse Diseases 0.000 claims description 4
- 208000019553 vascular disease Diseases 0.000 claims description 4
- 230000008673 vomiting Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 231100000736 substance abuse Toxicity 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 14
- PWVXXGRKLHYWKM-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 PWVXXGRKLHYWKM-LJQANCHMSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 11
- 229960002472 eletriptan Drugs 0.000 description 11
- 238000009472 formulation Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 150000002990 phenothiazines Chemical class 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.5〜200mg/mlのエレトリプタンヘミスルフェートおよび0.5〜 2.0%w/vのカフェインを含む水性医薬組成物。 2.40〜160mg/mlのエレトリプタンヘミスルフェートを含む、請求 項1記載の組成物。 3.60〜120mg/mlのエレトリプタンヘミスルフェートを含む、請求 項1または2記載の組成物。 4.1.0〜2.0%w/vのカフェインを含む、請求項1〜3のいずれか1 項記載の組成物。 5.さらに酸化防止剤を含む、請求項1〜4のいずれか1項記載の組成物。 6.酸化防止剤がクエン酸である、請求項5記載の組成物。 7.1.0%w/v以下のクエン酸が存在する、請求項6記載の組成物。 8.0.2〜0.4%w/vのクエン酸が存在する、請求項7記載の組成物。 9.酸化防止剤がアスコルビン酸である、請求項5記載の組成物。 10.さらにエタノールを含む、請求項1〜9のいずれか1項記載の組成物。 11.20.0%w/v以下のエタノールが存在する、請求項10記載の組成 物。 12.2.0〜10.0%w/vのエタノールが存在する、請求項11記載の 組成物。 13.2.0〜6.0%w/vのエタノールが存在する、請求項12記載の組 成物。 14.pH4.0〜9.0に緩衝化された、請求項1〜13のいずれか1項記 載の組成物。 15.pH7.5〜8.5に緩衝化された、請求項14記載の組成物。 16.pH4.0〜5.0に緩衝化された、請求項14記載の組成物。 17.120mg/mlのエレトリプタンヘミスルフェート、 1.5%w/vのカフェイン、 0.3%w/vのクエン酸、および 5%w/vのエタノール を含む水性組成物であって、pH7.5〜8.5、好ましくは約pH8.0に緩 衝化された、請求項1記載の組成物。 18.トリス(ヒドロキシメチル)メチルアミンおよび水酸化ナトリウムを用 いて緩衝化された、請求項17記載の組成物。 19.医薬として使用するための、請求項1〜18のいずれか1項記載の組成 物。 20.5−HT1受容体の選択的アゴニストの関与が示唆される疾病または状 態の処置に用いる医薬の製造のための、請求項1〜18のいずれか1項記載の組 成物の使用。 21.片頭痛、高血圧症、抑うつ症、嘔吐、不安、摂食障害、肥満症、薬物乱 用、群発性頭痛、痛み、慢性発作性片頭痛、および血管障害に伴う頭痛よりなる 群から選択される疾病または状態の処置に用いる医薬の製造のための、請求項1 〜18のいずれか1項記載の組成物の使用。 22.片頭痛の処置のための、請求項21記載の使用。 23.5−HT1受容体の選択的アゴニストの関与が示唆される疾病または状 態の処置のためにヒトを処置する方法であって、有効量の請求項1〜18のいず れか1項記載の組成物をヒトに投与することを含む方法。 24.片頭痛、高血圧症、抑うつ症、嘔吐、不安、摂食障害、肥満症、薬物乱 用、群発性頭痛、痛み、慢性発作性片頭痛、および血管障害に伴う頭痛よりなる 群から選択される疾病または状態の処置のためにヒトを処置する方法であって、 有効量の請求項1〜18のいずれか1項記載の組成物をヒトに投与することを含 む方法。 25.片頭痛の処置のための、請求項24記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9714081.8 | 1997-07-03 | ||
GBGB9714081.8A GB9714081D0 (en) | 1997-07-03 | 1997-07-03 | Pharmaceutical compositions |
GB9718270.3 | 1997-08-28 | ||
GBGB9718270.3A GB9718270D0 (en) | 1997-07-03 | 1997-08-28 | Pharmaceutical compositions |
PCT/EP1998/004176 WO1999001135A1 (en) | 1997-07-03 | 1998-07-01 | Pharmaceutical compositions containing eletriptan hemisulphate and caffeine |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000516262A true JP2000516262A (ja) | 2000-12-05 |
JP3350061B2 JP3350061B2 (ja) | 2002-11-25 |
Family
ID=26311826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50638199A Expired - Fee Related JP3350061B2 (ja) | 1997-07-03 | 1998-07-01 | エレトリプタンヘミスルフェートおよびカフェインを含有する医薬組成物 |
Country Status (31)
Country | Link |
---|---|
US (1) | US6166025A (ja) |
EP (1) | EP0999841B1 (ja) |
JP (1) | JP3350061B2 (ja) |
CN (1) | CN1145486C (ja) |
AT (1) | ATE206921T1 (ja) |
AU (1) | AU724728B2 (ja) |
BG (1) | BG103930A (ja) |
BR (1) | BR9810658A (ja) |
CA (1) | CA2292673C (ja) |
DE (1) | DE69802097T2 (ja) |
DK (1) | DK0999841T3 (ja) |
DZ (1) | DZ2549A1 (ja) |
EA (1) | EA002174B1 (ja) |
ES (1) | ES2163291T3 (ja) |
HK (1) | HK1029282A1 (ja) |
HR (1) | HRP990416B1 (ja) |
HU (1) | HUP0004468A3 (ja) |
ID (1) | ID24528A (ja) |
IL (1) | IL133206A0 (ja) |
IS (1) | IS5283A (ja) |
MA (1) | MA26518A1 (ja) |
NO (1) | NO312993B1 (ja) |
NZ (1) | NZ501419A (ja) |
OA (1) | OA11227A (ja) |
PL (1) | PL337803A1 (ja) |
PT (1) | PT999841E (ja) |
SI (1) | SI0999841T1 (ja) |
SK (1) | SK284462B6 (ja) |
TR (1) | TR199903332T2 (ja) |
UY (1) | UY25078A1 (ja) |
WO (1) | WO1999001135A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007533652A (ja) * | 2003-10-30 | 2007-11-22 | シプラ・リミテッド | 5−ht−受容体アゴニスト用経口製剤、その使用及びそれを用いた治療方法 |
JP2011510962A (ja) * | 2008-01-30 | 2011-04-07 | ペロヴィッチ,フィリップ | トリプタンの経口腔粘膜投与用製剤形態 |
JP2012036166A (ja) * | 2010-07-16 | 2012-02-23 | Taisho Pharmaceutical Co Ltd | 内服液剤 |
JP2012136512A (ja) * | 2010-12-10 | 2012-07-19 | Taisho Pharmaceutical Co Ltd | 内服液剤 |
JP2012136513A (ja) * | 2010-12-10 | 2012-07-19 | Taisho Pharmaceutical Co Ltd | 内服液剤 |
US8940714B2 (en) | 2003-03-04 | 2015-01-27 | Par Pharmaceutical, Inc. | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
JP2015180676A (ja) * | 2015-06-09 | 2015-10-15 | パル ファーマシューティカル, インコーポレーテッド | 鼻内送達用シアノコバラミン低粘度水性製剤 |
US9186374B2 (en) | 2005-08-17 | 2015-11-17 | Par Pharmaceutical, Inc. | Vitamin B12 nasal spray and method of use |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9816556D0 (en) * | 1998-07-30 | 1998-09-30 | Pfizer Ltd | Therapy |
GB9825988D0 (en) | 1998-11-27 | 1999-01-20 | Pfizer Ltd | Indole derivatives |
GB9922963D0 (en) | 1999-09-28 | 1999-12-01 | Pfizer Ltd | Polymorphic salt |
WO2000064448A1 (en) * | 1999-04-27 | 2000-11-02 | Board Of Regents, The University Of Texas System | A composition and method for treatment of cerebral ischemia |
GB9915231D0 (en) | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
IL136961A0 (en) * | 1999-06-30 | 2001-06-14 | Pfizer Prod Inc | 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine |
CO5190678A1 (es) * | 1999-06-30 | 2002-08-29 | Pfizer Prod Inc | Terapia combinada para el tratamiento de la migrana |
CO5190664A1 (es) * | 1999-06-30 | 2002-08-29 | Pfizer Prod Inc | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 |
GB9923314D0 (en) | 1999-10-01 | 1999-12-08 | Pfizer Ltd | Acylation process |
US6579898B2 (en) * | 2001-03-01 | 2003-06-17 | Pfizer Inc. | Compositions having improved bioavailability |
WO2003020977A2 (en) * | 2001-08-31 | 2003-03-13 | The University Court Of The University Of Glasgow | Nucleotide repeats assay |
GB0312478D0 (en) * | 2003-05-30 | 2003-07-09 | Pfizer Ltd | Improved process |
US7132549B2 (en) | 2003-05-30 | 2006-11-07 | Pfizer Inc. | Process |
US20080286388A1 (en) * | 2004-10-22 | 2008-11-20 | Shin-Jen Shiao | Pharmaceutical Composition and Non Dependence Coffee Comprising Edible Carboxylic Acid and/or Its Acid Salts and Coffeine |
US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
US8293489B2 (en) | 2007-01-31 | 2012-10-23 | Henkin Robert I | Methods for detection of biological substances |
US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
US8915245B2 (en) | 2010-10-07 | 2014-12-23 | Vapotherm, Inc. | Nebulizer systems, apparatus and methods for respiratory therapy |
US20160030435A1 (en) * | 2013-03-15 | 2016-02-04 | Robert I HENKIN | Phosphodiesterase inhibitor treatment |
WO2015021405A1 (en) | 2013-08-08 | 2015-02-12 | Vapotherm, Inc. | Respiratory therapy condensation adaptor |
NL1040474C2 (en) * | 2013-10-31 | 2015-05-04 | Veramed B V | Nasal compositions stimulating ciliary activity. |
US10598672B2 (en) | 2014-02-18 | 2020-03-24 | Cyrano Therapeutics, Inc. | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
FR3053334B1 (fr) * | 2016-06-30 | 2018-07-27 | L'oreal | Melange liquide contenant du 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one et de compose de xanthine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9417310D0 (en) * | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
-
1998
- 1998-07-01 PL PL98337803A patent/PL337803A1/xx unknown
- 1998-07-01 DK DK98940152T patent/DK0999841T3/da active
- 1998-07-01 CA CA002292673A patent/CA2292673C/en not_active Expired - Fee Related
- 1998-07-01 AT AT98940152T patent/ATE206921T1/de not_active IP Right Cessation
- 1998-07-01 WO PCT/EP1998/004176 patent/WO1999001135A1/en not_active Application Discontinuation
- 1998-07-01 DZ DZ980159A patent/DZ2549A1/xx active
- 1998-07-01 CN CNB988066289A patent/CN1145486C/zh not_active Expired - Fee Related
- 1998-07-01 US US09/402,239 patent/US6166025A/en not_active Expired - Fee Related
- 1998-07-01 AU AU88569/98A patent/AU724728B2/en not_active Ceased
- 1998-07-01 ID IDW991585A patent/ID24528A/id unknown
- 1998-07-01 PT PT98940152T patent/PT999841E/pt unknown
- 1998-07-01 NZ NZ501419A patent/NZ501419A/xx unknown
- 1998-07-01 SI SI9830068T patent/SI0999841T1/xx unknown
- 1998-07-01 SK SK1828-99A patent/SK284462B6/sk unknown
- 1998-07-01 EP EP98940152A patent/EP0999841B1/en not_active Expired - Lifetime
- 1998-07-01 MA MA25150A patent/MA26518A1/fr unknown
- 1998-07-01 IL IL13320698A patent/IL133206A0/xx unknown
- 1998-07-01 HU HU0004468A patent/HUP0004468A3/hu unknown
- 1998-07-01 DE DE69802097T patent/DE69802097T2/de not_active Expired - Fee Related
- 1998-07-01 EA EA199901100A patent/EA002174B1/ru not_active IP Right Cessation
- 1998-07-01 UY UY25078A patent/UY25078A1/es not_active IP Right Cessation
- 1998-07-01 JP JP50638199A patent/JP3350061B2/ja not_active Expired - Fee Related
- 1998-07-01 TR TR1999/03332T patent/TR199903332T2/xx unknown
- 1998-07-01 ES ES98940152T patent/ES2163291T3/es not_active Expired - Lifetime
- 1998-07-01 BR BR9810658-9A patent/BR9810658A/pt not_active Application Discontinuation
-
1999
- 1999-11-30 BG BG103930A patent/BG103930A/xx unknown
- 1999-11-30 IS IS5283A patent/IS5283A/is unknown
- 1999-12-01 NO NO19995887A patent/NO312993B1/no unknown
- 1999-12-03 OA OA9900271A patent/OA11227A/en unknown
- 1999-12-30 HR HR970276A patent/HRP990416B1/xx not_active IP Right Cessation
-
2001
- 2001-01-05 HK HK01100144A patent/HK1029282A1/xx unknown
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8940714B2 (en) | 2003-03-04 | 2015-01-27 | Par Pharmaceutical, Inc. | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
US9415007B2 (en) | 2003-03-04 | 2016-08-16 | Par Pharmaceutical, Inc. | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
JP2007533652A (ja) * | 2003-10-30 | 2007-11-22 | シプラ・リミテッド | 5−ht−受容体アゴニスト用経口製剤、その使用及びそれを用いた治療方法 |
US9186374B2 (en) | 2005-08-17 | 2015-11-17 | Par Pharmaceutical, Inc. | Vitamin B12 nasal spray and method of use |
US10052344B2 (en) | 2005-08-17 | 2018-08-21 | Endo Pharmaceuticals Inc. | Vitamin B12 nasal spray and method of use |
JP2011510962A (ja) * | 2008-01-30 | 2011-04-07 | ペロヴィッチ,フィリップ | トリプタンの経口腔粘膜投与用製剤形態 |
JP2012036166A (ja) * | 2010-07-16 | 2012-02-23 | Taisho Pharmaceutical Co Ltd | 内服液剤 |
JP2012136512A (ja) * | 2010-12-10 | 2012-07-19 | Taisho Pharmaceutical Co Ltd | 内服液剤 |
JP2012136513A (ja) * | 2010-12-10 | 2012-07-19 | Taisho Pharmaceutical Co Ltd | 内服液剤 |
JP2015180676A (ja) * | 2015-06-09 | 2015-10-15 | パル ファーマシューティカル, インコーポレーテッド | 鼻内送達用シアノコバラミン低粘度水性製剤 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3350061B2 (ja) | エレトリプタンヘミスルフェートおよびカフェインを含有する医薬組成物 | |
HU199678B (en) | Process for producing aerosols containing nitroglicerol | |
US6485706B1 (en) | Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same | |
EP0524587B1 (en) | Therapeutic compositions for intranasal administration which include ketorolac TM | |
KR20000023708A (ko) | 염기성 약물의 산부가염을 함유하는 제약 조성물 | |
FR2670487A1 (fr) | Nouveau sel de 3-[2-dimethylamino)ethyl-]-n-methyl-1h-indole-5-methanesulfonamide, sa preparation et son utilisation comme medicament. | |
JP2003505403A (ja) | 経鼻抗痙攣組成物及び調節方法 | |
US6193954B1 (en) | Formulations for pulmonary delivery of dopamine agonists | |
US6007834A (en) | Nasal melatonin composition | |
JPH0140804B2 (ja) | ||
RU2130022C1 (ru) | N,n-диметил-2-[5-(1,2,4-триазол-1-илметил)-1н-индол-3-ил] этиламина сульфатная соль (2:1) и ее фармацевтически приемлемые гидраты, способы ее получения, фармацевтическая композиция на ее основе, способ ее получения и лекарственное средство | |
GB2162745A (en) | Nasal compositions | |
AU743492B2 (en) | New formulation for the oromucosal, in particular pernasal, route | |
US5093127A (en) | Preparation of fr115224 substrate for parenteral administration | |
KR100384346B1 (ko) | 엘레트립탄 헤미술페이트 및 카페인을 포함하는 약제학적조성물 | |
JP2001527037A (ja) | Z−4−ヒドロキシタモキシフェン及びシクロデキストリンを含む混合物及び薬剤学的組成 | |
JP2001335508A (ja) | プラルモレリン含有点鼻用製剤 | |
MXPA99011299A (en) | Pharmaceutical compositions containing eletriptan hemisulphate and caffeine | |
JPH11501916A (ja) | あるシスチン誘導体の薬理学的使用 | |
US20230143212A1 (en) | Pharmaceutical Preparations Of Melatonin Suitable For Intranasal Administration | |
JP2905532B2 (ja) | 抗喘息薬 | |
CZ466099A3 (cs) | Farmaceutické kompozice obsahující elektriptanhemisulfat a kofein | |
HU211543A9 (hu) | Hajtógáz nélküli nitroglicerin aeroszol helyi alkalmazás céljára Az átmeneti oltalom az 1-5. igénypontokra vonatkozik. | |
JPH09227366A (ja) | 抗炎症剤 | |
WO2004087147A1 (ja) | 肺疾患の治療および/または予防剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070913 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080913 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080913 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090913 Year of fee payment: 7 |
|
LAPS | Cancellation because of no payment of annual fees |